Which of the following organs is a target for prolactin?

Correct Answer: D

Rationale: The correct answer is D, the mammary gland. Prolactin is a hormone primarily responsible for mammary gland development and milk production in females. It stimulates the mammary alveolar cells to produce milk. The other choices, A: Liver, B: Adrenal cortex, and C: Thyroid, are not directly targeted by prolactin and do not have a primary role in milk production. Therefore, the correct answer is D as it directly correlates with the function of prolactin in the body.

Correct Answer: C

Rationale: The correct answer is C: Meclofenamic acid. Fenamate derivatives are a specific class of NSAIDs that have a fenamic acid structure. Meclofenamic acid is a fenamate derivative as it contains the fenamic acid structure, making it the correct choice. A: Phenylbutazone is not a fenamate derivative, it belongs to the pyrazolidinedione class. B: Indomethacin is not a fenamate derivative, it belongs to the indoleacetic acid class. D: Diclofenac is not a fenamate derivative, it belongs to the acetic acid class.

Correct Answer: D

Rationale: The correct answer is D: 21 days. The half-life of I.V. IgG preparation is significantly longer compared to the other options. IgG has a long half-life of approximately 21 days due to its structural properties that allow it to circulate in the body for an extended period. This prolonged half-life is crucial for maintaining therapeutic levels of IgG in the body over an extended period. Options A, B, and C have much shorter half-lives compared to IgG, making them incorrect choices for this question.

Correct Answer: C

Rationale: The correct answer is C: Pyridoxine. Isoniazid used in tuberculosis treatment can lead to pyridoxine deficiency, causing peripheral neuropathy. Therefore, supplementing with pyridoxine is essential. Nicotinic acid (A) is not directly related to isoniazid therapy. Riboflavin (B) deficiency is not a common issue with isoniazid. Ascorbic acid (D) does not play a role in preventing isoniazid-induced neuropathy.

Correct Answer: A

Rationale: The correct answer is A: TRUE. Lovastatin combined with a bile-acid binding resin has been shown to cause regression of coronary lesions in about one third of treated patients. This is supported by clinical studies and research, demonstrating the effectiveness of this combination therapy in improving coronary health. The other choices are incorrect because they do not accurately reflect the evidence and outcomes of this specific treatment approach. Choice B (FALSE) is incorrect because there is evidence to support the regression of coronary lesions with this treatment. Choice C (All) is incorrect because not all patients treated with this combination therapy experience regression of coronary lesions. Choice D (None) is incorrect as there is a significant proportion of patients who do benefit from this treatment in terms of lesion regression.